Rani Therapeutics Holdings (RANI) Short term Debt (2020 - 2025)

Rani Therapeutics Holdings has reported Short term Debt for 5 years, with the latest figure at $13.5 million in Q3 2025.

• On a quarterly basis, Short term Debt fell 8.34% year-over-year to $13.5 million in Q3 2025; TTM through Sep 2025 was $13.5 million, a 8.34% decrease from a year earlier, with the FY2024 full-year figure at $15.0 million, up 206.31% from the prior year.
• Short term Debt was $13.5 million for Q3 2025 at Rani Therapeutics Holdings, down from $15.0 million in the prior quarter.
• The five-year high for Short term Debt was $15.0 million in Q4 2024, with the low at $1.2 million in Q3 2023.
• Average Short term Debt over 4 years is $10.4 million, with a median of $12.9 million recorded in 2024.
• The sharpest annual moves came in 2024 and 2025: Short term Debt jumped 1108.51% in 2024, then dropped 8.34% in 2025.
• Over 4 years, Short term Debt stood at $3.9 million in 2021, then increased by 26.08% to $4.9 million in 2023, then jumped by 206.31% to $15.0 million in 2024, then dropped by 9.75% to $13.5 million in 2025.
• The last three Short term Debt figures came in at $13.5 million (Q3 2025), $15.0 million (Q2 2025), and $15.0 million (Q1 2025), per Business Quant data.